The next six months will be full of dramatic moments for the biotechnology industry. The Food and Drug Administration will either be validated or undermined for its decision to grant an early approval to the first gene therapy for Duchenne muscular dystrophy. A non-addictive pain pill could finally materialize, or fall short like others before it. A closely watched group of cancer drugs might rebound after a series of setbacks, while another could show a new way to treat multiple sclerosis. And a popular group of diabetes and weight-loss drugs will get data on whether they prevent heart attacks, too.
These moments are tied to some of the top clinical trial readouts to expect by the end of this year. Here are 10 to watch, and why they’re important: READ MORE
By BioPharma Dive Staff
Source: biopharmadive.com
After attending the annual Pulmonary Embolism Symposium last week in Austin, Texas, the analysts predicted clinical guidelines could shift toward catheter-based therapy once data from ongoing randomized trials is available.
SAS – the AI and analytics company – has been selected by AstraZeneca to help boost efficiency and drive automation in the delivery of statistical analyses for clinical and post-approval submissions to regulatory authorities.
After the Centers for Medicare & Medicaid Services (CMS) revealed the list of drugs set to face the first round of price negotiations under the Inflation Reduction Act (IRA), the drugmakers responsible for marketing them are confronting a series of deadlines.
